Shares of medical device developer Aethlon Medical (AEMD.O) soared 430% to $7.58 premarket after the company entered an all-stock merger agreement with private biotech company North Immunology.
If gains hold, the stock is set to open at its highest since June 2026.
The combined company is expected to operate as North Immunology and trade under the ticker NRTX, with a pro forma equity value of $346.5 million.
AEMD shareholders are expected to own about 4.75% of the combined company.
The deal includes a $180 million private placement expected to fund the combined company’s operations into H2 2028.
Through last close, AEMD was valued at $2.3 million after losing about 90% year to date.
AEMD•
